Eradiquer la Grippe ou la Malaria, thérapie contre de nombreux cancer … mais ou sont les Français (Hypocondriaque) et Sanofi ?!
One fascinating area of healthcare right now is the potential development of mRNA-based therapies beyond the COVID-19 vaccines. The Atlantic explores how mRNA technology could change the world.
But mRNA’s story likely will not end with COVID-19: Its potential stretches far beyond this pandemic. This year, a team at Yale patented a similar RNA-based technology to vaccinate against malaria, perhaps the world’s most devastating disease. Because mRNA is so easy to edit, Pfizer says that it is planning to use it against seasonal flu, which mutates constantly and kills hundreds of thousands of people around the world every year. The company that partnered with Pfizer last year, BioNTech, is developing individualized therapies that would create on-demand proteins associated with specific tumors to teach the body to fight off advanced cancer. In mouse trials, synthetic-mRNA therapies have been shown to slow and reverse the effects of multiple sclerosis.
“I’m fully convinced now even more than before that mRNA can be broadly transformational,” Özlem Türeci, BioNTech’s chief medical officer, told me. “In principle, everything you can do with protein can be substituted by mRNA.”
A newly developed hydrogen successfully reverted cancer cells to cancer stem cells within 24 hours, in six different types of human cancer (see the paper).
This study paves the way for research into drugs that can target cancer stem cells. “In the future, the DN gel could be used to enhance cancer cell type diagnosis and to produce personalized medicines, which could improve the prognosis of cancer patients,” said Shinya Tanaka.
via Chrome : lire l’article source